RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Oxford Biomedica EBIT 2024

Oxford Biomedica EBIT

-40.58 M GBP

Oxford Biomedica Dividend yield

Ticker

OXB.L

ISIN

GB00BDFBVT43

WKN

A2JLRX

In 2024, Oxford Biomedica's EBIT was -40.58 M GBP, a -52.81% increase from the -85.98 M GBP EBIT recorded in the previous year.

The Oxford Biomedica EBIT history

YEAREBIT (undefined GBP)
2027e24.41
2026e5.2
2025e-23.87
2024e-40.58
2023-85.98
2022-51.56
202120.93
2020-4.86
2019-12.58
20187.93
2017-7.97
2016-11.31
2015-14.08
2014-10.61
2013-12.82
2012-10.49
2011-11.3
2010-8.06
2009-2.17
2008-9.11
2007-19.49
2006-21.1
2005-11.23
2004-12.65

Oxford Biomedica Aktienanalyse

What does Oxford Biomedica do?

Oxford BioMedica PLC is a biopharmaceutical company based in Oxford, England. The company was founded in 1995 and has since become a leading provider of gene therapy products. The company's business model is to develop, produce, and market gene therapies for rare diseases and cancer. Oxford BioMedica utilizes modern technologies, such as viral vectors, to introduce genetic material into diseased cells and correct their function. One of the company's main areas of focus is the development of gene therapies for rare diseases. Oxford BioMedica has several promising products in this field, including gene therapies for metabolic disorders, muscular diseases, and eye diseases. Another important area for the company is the development of cancer immunotherapies. Oxford BioMedica is working on the development of gene therapies that activate the body's immune system to specifically target cancer cells. Among the products that Oxford BioMedica has already brought to market is the gene therapy product Strimvelis, which is used to treat severe combined immunodeficiency (SCID). Through treatment with Strimvelis, children with SCID can lead a normal life and are no longer confined to sterile environments. Another well-known product from Oxford BioMedica is the gene therapy product OXB-102, which is being tested in phase III clinical trials for the treatment of Parkinson's disease. In this therapy, a viral vector is used to correct a genetic mutation in the affected brain cells and alleviate the symptoms of Parkinson's. In recent years, Oxford BioMedica has also formed significant partnerships with major pharmaceutical and biotech companies such as Novartis, Sanofi, and Bioverativ to further develop and bring its gene therapy technology and products to market. Overall, Oxford BioMedica is a leading company in the field of gene therapy. With a strong pipeline of promising products and significant partnerships with the pharmaceutical industry, the company is well positioned to continue growing and contribute to the cure of diseases. Oxford Biomedica ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Oxford Biomedica's EBIT

Oxford Biomedica's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Oxford Biomedica's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Oxford Biomedica's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Oxford Biomedica’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Oxford Biomedica Stock

How much did Oxford Biomedica achieve in EBIT for the current year?

In the current year, Oxford Biomedica has achieved an EBIT of -40.58 M GBP.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Oxford Biomedica.

How has the EBIT of Oxford Biomedica developed in recent years?

The EBIT of Oxford Biomedica has increased by -52.808% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Oxford Biomedica?

The EBIT of Oxford Biomedica is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Oxford Biomedica pay?

Over the past 12 months, Oxford Biomedica paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oxford Biomedica is expected to pay a dividend of 0 GBP.

What is the dividend yield of Oxford Biomedica?

The current dividend yield of Oxford Biomedica is .

When does Oxford Biomedica pay dividends?

Oxford Biomedica pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oxford Biomedica?

Oxford Biomedica paid dividends every year for the past 0 years.

What is the dividend of Oxford Biomedica?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oxford Biomedica located?

Oxford Biomedica is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oxford Biomedica kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oxford Biomedica from 5/30/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 5/30/2024.

When did Oxford Biomedica pay the last dividend?

The last dividend was paid out on 5/30/2024.

What was the dividend of Oxford Biomedica in the year 2023?

In the year 2023, Oxford Biomedica distributed 0 GBP as dividends.

In which currency does Oxford Biomedica pay out the dividend?

The dividends of Oxford Biomedica are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Oxford Biomedica stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Oxford Biomedica

Our stock analysis for Oxford Biomedica Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oxford Biomedica Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.